- Research Article
- Open Access
Adipocyte Enhancer-Binding Protein 1 (AEBP1) (a Novel Macrophage Proinflammatory Mediator) Overexpression Promotes and Ablation Attenuates Atherosclerosis in ApoE−/− and LDLR−/− Mice
Molecular Medicine volume 17, pages 1056–1064 (2011)
Atherogenesis is a long-term process that involves inflammatory response coupled with metabolic dysfunction. Foam cell formation and macrophage inflammatory response are two key events in atherogenesis. Adipocyte enhancer-binding protein 1 (AEBP1) has been shown to impede macrophage cholesterol efflux, promoting foam cell formation, via peroxisome proliferator-activated receptor (PPAR)-γl and liver X receptor α (LXRα) downregulation. Moreover, AEBP1 has been shown to promote macrophage inflammatory responsiveness by inducing nuclear factor (NF)-κB activity via IκBα downregulation. Lipopolysaccharide (LPS)-induced suppression of pivotal macrophage cholesterol efflux mediators, leading to foam cell formation, has been shown to be mediated by AEBP1. Herein, we showed that AEBP1-transgenic mice (AEBP1TG) with macrophage-specific AEBP1 overexpression exhibit hyperlipidemia and develop atherosclerotic lesions in their proximal aortas. Consistently, ablation of AEBP1 results in significant attenuation of atherosclerosis (males: 3.2-fold, P = 0.001 (en face)), 2.7-fold, P = 0.0004 (aortic roots); females: 2.1-fold, P = 0.0026 (en face), 1.7-fold, P = 0.0126 (aortic roots)) in the AEBP1−/−/low-density lipoprotein receptor (LDLR)−/− double-knockout (KO) mice. Bone marrow (BM) transplantation experiments further revealed that LDLR−/− mice reconstituted with AEBP1−/−/LDLR−/− BM cells (LDLR−/−/KO-BM chimera) display significant reduction of atherosclerosis lesions (en face: 2.0-fold, P = 0.0268; aortic roots: 1.7-fold, P = 0.05) compared with control mice reconstituted with AEBP1+/+/LDLR−/− BM cells (LDLR−/−/WT-BM chimera). Furthermore, transplantation of AEBP1TG BM cells with the normal apolipoprotein E (ApoE) gene into ApoE−/− mice (ApoE−/−/TG-BM chimera) leads to significant development of atherosclerosis (males: 2.5-fold, P = 0.0001 (en face), 4.7-fold, P = 0.0001 [aortic roots]; females: 1.8-fold, P = 0.0001 (en face), 3.0-fold, P = 0.0001 [aortic roots]) despite the restoration of ApoE expression. Macrophages from ApoE−/−/TG-BM chimeric mice express reduced levels of PPARγ1, LXRα, ATP-binding cassette A1 (ABCA1) and ATP-binding cassette G1 (ABCG1) and increased levels of the inflammatory mediators interleukin (IL)-6 and tumor necrosis factor (TNF)-α compared with macrophages of control chimeric mice (ApoE−/−/NT-BM) that received AEBP1 nontransgenic (AEBP1NT) BM cells. Our in vivo experimental data strongly suggest that macrophage AEBP1 plays critical regulatory roles in atherogenesis, and it may serve as a potential therapeutic target for the prevention or treatment of atherosclerosis.
Atherosclerosis is a killer disease responsible for >50% of deaths in the developed world (1,2). Although some researchers seem to focus on atherosclerosis as either a metabolic/lipid disorder or an inflammatory disorder, there is a general consensus among most investigators that atherosclerosis is a complex disease involving both metabolic and inflammatory dysfunctions. Once fully differentiated in the intima, macrophages express a wide range of scavenger receptors that allow internalization of modified low-density lipoprotein (LDL). Lipid accumulation in macrophages leads to the activation of signaling pathways that involve activation of peroxisome proliferator-activated receptor (PPAR)-γl and liver X receptor a (LXRα), nuclear receptors that function as transcription factors controlling macrophage cholesterol homeostasis (3–7). Ligand-bound activated PPARγl and LXRα are synergistically implicated in the transactivation of several genes for which products are critically involved in mediating macrophage cholesterol efflux and initiating reverse cholesterol transport. Genetic defects or pharmacological inhibition of any component of the macrophage cholesterol efflux pathway leads to an imbalance in cholesterol homeostasis. This result eventually leads to massive accumulation of lipids in the cytoplasmic compartment of macrophages, which acquire a foamy appearance and transform into lipid-engorged foam cells, a hallmark of fatty streak and atherosclerotic lesion formation. Because atherosclerosis is a multigenic disease, understanding the roles and expression patterns of genes with known and unknown functions is critical in understanding the molecular mechanisms underlying atherogenesis.
Adipocyte enhancer-binding protein 1 (AEBP1) is a ubiquitously expressed transcriptional repressor for which expression is highest in white and brown adipose tissues, liver, lung, spleen and brain (8). Recently, AEBP1 was shown to be abundantly expressed in primary macrophages and macrophage cell lines (9–11). We demonstrated that AEBP1 represses the expression of PPARγ1 and LXRα in a dose-dependent, DNA binding-dependent fashion, which is accompanied by concurrent repression of major cholesterol efflux mediators (for example, ATP-binding cassette A1 (ABCA1), ATP-binding cassette G1 (ABCG1) and apolipoprotein [Apo]-E), leading to foam cell formation (9). AEBP1 was also shown to promote macrophage inflammatory responsiveness by inducing nuclear factor (NF)-κB activity via IκBα-negative regulation through protein-protein interaction (10). These experimental findings strongly suggest that AEBP1 may exert potent atherogenic effects in vivo. We hypothesize that AEBP1 overexpression promotes lesion formation, while AEBP1 ablation attenuates lesion formation in ApoE−/− and low-density lipoprotein receptor (LDLR)−/− murine models of atherosclerosis.
In this study, ablation of AEBP1 (12) in the LDLR−/− mice (AEBP1−/−/LDLR−/−), LDLR−/− mice receiving AEBP1−/−/LDLR−/− bone marrow (BM) cells and ApoE−/− mice receiving BM cells from AEBP1TG mice (13) that overexpress AEBP1 in macrophages were used as invaluable in vivo tools to assess the involvement of AEBP1 in atherosclerotic lesion formation. Remarkably, AEBP1 ablation significantly reduced atherosclerosis in LDLR −/−mice challenged with an atherogenic diet. Moreover, LDLR −/−mice receiving BM cells from LDLR−/−/AEBP1−/− mice exhibited marked reduction of atherosclerosis. In contrast, transplantation of BM cells with the wild-type ApoE gene from AEBP1TG mice into ApoE−/− mice did not ameliorate atherosclerosis; rather, it led to enhanced lesion formation. Collectively, our findings clearly demonstrate that AEBP1 manifests itself as a potent pro-atherogenic factor. We anticipate that AEBP1 may serve as a likely molecular target for developing novel therapeutic strategies for the prevention or treatment of atherosclerosis.
Materials and Methods
AEBP1−/− mice (12) were bred with LDLR−/− mice (The Jackson Laboratory, Bar Harbor, ME, USA). Intercrosses of AEBP1−/−/LDLR −/− mice yielded offspring that entered the study. Genotyping for AEBP1 and LDLR was performed by polymerase chain reaction (PCR). For analysis of atherosclerosis, mice were fed an atherogenic diet (high-cholesterol diet [HCD]) (40 kcal % fat, 1.25% cholesterol, 0% cholic acid; D12108C; Research Diets, New Brunswick, NJ, USA) beginning at 3 wks of age for a period of 13 wks. For high-fat diet (HFD) feeding experiments, mice were fed HFD (45 kcal % fat, 0.05% cholesterol, 0% cholic acids; D12451; Research Diets) beginning at 3wks of age.
BM cells were collected from the femurs and tibias of donor mice. Total Tcells were depleted using CD90.2 microbeads (EasySep, StemCell Technologies, BC, Canada). Recipient ApoE−/− (The Jackson Laboratory) and LDLR−mice at the age of 8–10 wks were lethally irradiated (800 rad) and then injected with BM cells (2 × 106) through the tail vein. Two weeks after BM transplantation, mice were placed on an atherogenic diet for 16 wks and then sacrificed to isolate BM cells and spleens for real-time PCR.
Mice were deeply anesthetized with isoflurane, and blood was obtained by intracardiac puncture. Plasma cholesterol and triglyceride levels were determined by enzymatic assays (Roche Diagnostics, Laval, QC, Canada, and Sigma, St. Louis, MO, USA). The aortas and hearts were isolated for en face and aortic root atherosclerotic lesion analysis.
All animal experiments were performed according to procedures approved by the Institutional Animal Care Committee (Carleton Animal Care Facility, Dalhousie University, Halifax, NS, Canada). Age-matched mice were kept on a 12-h light cycle.
Atherosclerotic Lesion Analysis
For en face analysis, aorta isolation and detection of atherosclerotic lesions using sudan IV were performed as previously described (14), and images were captured with a PixeLINK PL-A686C camera attached to a Leica MZ6 dissecting microscope. Aortic cryosection analysis of atherosclerotic lesions in the proximal aortic root was performed as previously described (15), and photomicroscopy was performed on a Nikon Eclipse E600 microscope attached to a Nikon Coolpix 990 camera. In all cases, the percentage of stained lesion size was determined using ImageJ analysis software.
Immunohistochemistry for Aortic Cryosection
The hearts were harvested from AEBP1+/+/LDLR−/− and AEBP1−/−/LDLR−/− mice fed an atherogenic diet for 13 wks and were fixed in 10% buffered formalin overnight. The next day, the hearts were put in 0.02% sodium azide in phosphate-buffered saline. Consecutive 5-μm cryosections of the heart from the aortic sinus to the beginning of the aortic arch were subjected to immunohistochemistry using rat anti-mouse F4/80 (Abcam, San Francisco, CA, USA) for macrophage detection, rat anti-mouse CD106 for vascular cell adhesion molecule 1 (VCAM-1) detection (BD Pharmingen, San Diego, CA, USA), rat anti-mouse CD3 for T-cell detection (BD Pharmingen) and normal rat IgG as a negative control.
Macrophages were isolated from the spleen using EasySep specific antibodies and tiny fluorescence-activated cell sorter (FACS)-compatible magnetic nanoparticles in a column-free magnetic system (StemCell Technologies). Purity (~98%) was confirmed by flow cytometry.
RNA and Protein Analysis
Total RNA was isolated from the spleen and BM cells using TRIZOL (Invitrogen, Burlington, ON, Canada) and was then reverse-transcribed into cDNA using an iScript cDNA synthesis kit (Bio-Rad, Mississauga, ON, Canada). PCR was performed using a CFX96 optical reaction module (Bio-Rad). Protein extraction and immunoblotting were performed as previously described (13).
Group means were compared with a Student t test. A probability value of ≤0.05 was considered statistically significant. All data are reported as mean ± standard error of the mean (SEM) as indicated.
All supplementary materials are available online at www.molmed.org .
AEBP1TG Mice Exhibit Signs of Atherosclerotic Lesion Formation in a Gender-Influenced Manner
The fact that AEBP1 overexpression causes cholesterol homeostasis imbalance in macrophages (9,11) prompted us to examine the serum lipid profile in AEBP1TG mice that overexpress AEBP1 in macrophages (9). Serum samples obtained from 32-wk-old, HFD-fed AEBP1TG females had significantly higher serum cholesterol and triglyceride levels than samples from AEBP1NT females (cholesterol, 179 ± 6.2 and 128 ± 7.3 mg/dL, P < 0.05; triglyceride, 143 ± 12.3 and 100 ± 9.3 mg/dL, P < 0.05, respectively). Although AEBP1TG males have higher serum cholesterol and triglyceride levels than AEBP1NT males, this difference did not reach statistical significance (Figure 1A). We have previously shown that while triglyceride serum levels are significantly lower in AEBP1−/− mice compared with AEBP1+/+ mice, cholesterol serum levels are only significantly lower in AEBP1 −/− males, not females (12). Collectively, these findings suggest that AEBP1 may exert potent atherogenic effects in vivo. To investigate this possibility, proximal aortic cryosections obtained from young (12-wk) and old (32-wk), chow- and HFD-fed AEBP1TG, AEBP1NT, AEBP1+/+ and AEBP1−/− mice were assessed for atherosclerotic lesion formation. Lesions were detected only in the HFD-fed AEBP1TG mice (Table 1). Compared with ApoE−/− and LDLR−/− mice, HFD-fed AEBP1TG mice develop relatively small, atypical atherosclerotic lesions that are surrounded by very thin, poorly characterized fibrous caps (Figures 1B, D). Additionally, lesions detected in AEBP1TG mice are not continuous along the endothelial monolayer. Interestingly, although lesions are detected in both genders of AEBP1TG mice, females develop lesions more prevalently (see Table 1) and of a larger mean area (Table 2).
AEBP1 Ablation Reduces Atherosclerotic Lesion Area and Macrophage Infiltration into the Aortic Sinus
Because AEBP1−/− mice were raised on C57BL/6 background (12) and AEBP1−/− macrophages exhibit enhanced cholesterol efflux and diminished inflammatory responsiveness (9), we anticipated that AEBP1−/−/ApoE−/− and AEBP1−/−/ LDLR−/− double-knockout mice would be resistant to atherosclerotic lesion formation. Because of embryonic lethality in the AEBP1−/−/ApoE−/− double-knockout mice, we were only able to generate AEBP1−/−/LDLR−/− double-knockout mice. To assess the effect of AEBP1 ablation on atherogenesis, groups of AEBP1+/+/LDLR−/− and AEBP1−/−/LDLR−/− litter-mates were placed on an atherogenic diet for 13 wks. Subsequently, atherosclerotic lesion formation was assessed by en face analysis (Figure 2A). Computational analysis revealed a significant reduction in lesion size in male (3.2-fold, P = 0.001; 3.9% versus 12.4% lesion area) and female (2.1-fold, P = 0.0026; 5.6% versus 11.8% lesion area) AEBP1−/−/LDLR−/− mice (Figure 2b). Consistently, histological analysis of the aortic roots revealed a remarkable attenuation of lesion formation in AEBP1−/−/LDLR−/− mice compared with AEBP1+/+/LDLR−/− littermates (Figure 2C). Quantification of lesion size revealed a significant decrease of lesion area in male (2.7-fold, P = 0.0004; 9.8% versus 26% lesion area) and female (1.7-fold, P = 0.0126; 19.5% versus 33.7%) AEBP1−/− LDLR−/− mice compared with AEBP1+/+/ LDLR−/− littermates (Figure 2D).
To experimentally address whether AEBP1 deficiency causes impaired recruitment of monocytes into the developing lesions, we investigated the migration and homing of macrophages into the atherosclerotic lesions of AEBP1−/−/LDLR−/− mice. As shown in Figure 2E, homing of macrophages (F4/80) into the lesions was reduced in AEBP1−/−/LDLR −/−mice compared with AEBP1+/+/LDLR−/− controls. VCAM-1 is known to be crucial for monocyte extravasation into atherosclerotic lesions (16). Immunohistochemical analysis using rat anti-mouse CD106 primary antibody revealed that VCAM-1 expression is also reduced in the lesions of AEBP1−/−/LDLR−/− mice (see Figure 2E), suggesting that AEBP1 ablation impairs macrophage infiltration into atherosclerotic lesions via the inhibition of VCAM-1 expression. It has been reported that advanced atherosclerotic lesions gradually accumulate T cells (17). Immunostaining of aortic sinus sections revealed a clear reduction in T-cell numbers (CD3) in the lesions of AEBP1−/−/LDLR−/− mice (see Figure 2E), indicating that AEBP1 ablation also attenuates the accumulation of T cells in atherosclerotic lesions.
AEBP1 Deficiency Influences Lipid and Energy Metabolism in LDLR−/− Mice
Interestingly, the attenuation of lesion formation in AEBP1−/−/LDLR −/− mice occurred in the absence of a significant change in serum lipid profile, except for plasma cholesterol levels, which were significantly (P = 0.034) lower in AEBP1−/−/LDLR−/− females than in the AEBP1+/+/LDLR−/− counterparts (Figure 3A). Although plasma triglyceride levels were lower in AEBP1−/−/LDLR−/− mice than in AEBP1+/+/LDLR −/− controls for both genders (1.49-fold in males and 1.37-fold in females), this difference did not reach statistical significance. We have previously reported that AEBP1−/− mice display resistance to diet-induced obesity and reduction in adipose tissue mass (12). Weekly body weight measurement showed that the starting body weight of AEBP1−/−/LDLR−/− mice was also lower than that of AEBP1+/+/LDLR−/− mice and that the difference in body weight was maintained over the course of the experiment (Figure 3B). However, energy intake was not significantly different between AEBP1−/−/LDLR−/− and AEBP1+/+/LDLR−/− males (Fi gure 3C), despite the significant (P = 0.004) reduction in feed efficiency of those males (Figure 3D). Although AEBP1−/−/LDLR−/− females display significantly (P = 0.006) increased energy intake (see Figure 3C), their body weight values were slightly, but not significantly, reduced (see Figure 3D). Taken together, these results demonstrate that AEBP1 ablation not only attenuates atherosclerotic lesion development in vivo, but also possibly influences lipid and energy metabolism.
BM-Derived AEBP1 Is Critical in Atherogenesis
We have previously shown that AEBP1 plays a key functional role in modulating in vivo adiposity and energy metabolism (12,13). Experimental evidence suggesting that adipose tissue pathophysiology (often exacerbated by obesity) strongly correlates with atherosclerosis is overwhelming (18). Although AEBP1−/− / LDLR−/− mice displayed significant resistance to atherosclerotic lesion development (Figure 2), the results may be due to a compound effect of global, systemic disruption of AEBP1 in these mice. To address this issue, chimeric mice were generated by BM transplantation to enable investigation of a direct and specific role of macrophage AEBP1 in atherogenesis. To examine whether attenuation of atherosclerosis in AEBP1−/−/LDLR−/− mice is macrophage-driven and not systemic, we transplanted AEBP1−/−/ILDLR−/− BM cells into γ-irradiated LDLR−/− mice. Because AEBP1−/− macrophages exhibit enhanced cholesterol efflux and diminished inflammatory responsiveness (9–11), we anticipated that transplantation of BM cells from AEBP1−/−/LDLR−/− mice into LDLR−/− mice would result in amelioration or attenuation of atherogenesis. Female LDLR−/− recipients were reconstituted with male AEBP1−/−/LDLR−/− or AEBP1+/+/LDLR−/− BM cells, whereas male LDLR−/− recipients were reconstituted with female AEBP1−/−/LDLR−/− or AEBP1+/+/LDLR−/− BM cells (Figure 4A). Sixteen weeks after transplantation, genomic DNA from BM cells was extracted and the engraftment of donor cells was confirmed by real-time PCR analysis of the sex-determining region Y (SRY) gene in the Y chromosome. En face analysis shows that the lesion area in LDLR−/− mice that received AEBP1−/−/LDLR−/− BM cells (LDLR−/−/KO-BM chimera) is significantly reduced compared with control mice (LDLR−/−/WT-BM chimera) that received AEBP1+/+/LDLR−/− BM cells (2.0-fold, P = 0.0268) (Figure 4B). Consistently, aortic root sections stained with oil red O (ORO) also revealed reduced (1.7-fold, P = 0.05) accumulation of lipid deposits in the aortas of LDLR−/−/KO-BM mice compared with the control mice LDLR−/−/WT-BM (Figure 4C). Interestingly, the attenuation of atherosclerotic lesion formation in LDLR−/−/KO-BM occurred in the absence of a significant change in plasma cholesterol levels (Figure 4D); however, triglyceride levels (Figure 4E) were significantly (P = 0.006) reduced in LDLR−/−/KO-BM mice compared with the control mice LDLR−/−/WT-BM.
To further confirm that macrophage AEBP1 plays a critical role in the development of atherosclerosis, we generated more BM-chimeric mice, using the ApoE−/− background mice, to enable investigation of a direct and specific role of macrophage AEBP1 in atherosclerotic lesion formation. To this end, BM cells from AEBP1TG mice were transplanted into γ-irradiated ApoE−/− mice at the age of 10 wks. Female ApoE−/− recipients were reconstituted with male AEBP1TG or AEBP1NT BM cells, whereas male ApoE−/−recipients were reconstituted with female AEBP1TG or AEBP1NT BM cells (Figure 5A). As expected, transplantation of AEBP1NT macrophages with the normal ApoE gene into ApoE−/− mice (ApoE−/−/NT-BM) resulted in expression of ApoE (Figure 6C) and significant protection from diet-induced atherosclerosis. The extent of lesion in ApoE−/−/NT-BM mice (<10%) (Figure 5B) is markedly less than the level normally seen in ApoE−/−mice fed an atherogenic diet (>40%). In contrast, en face aorta analysis showed robust formation of atherosclerotic lesions in mice that received AEBP1TG BM cells (ApoE−/−/TG-BM) (see Figure 5B). Interestingly, male ApoE−/−/TG-BM mice displayed slightly more advanced atherosclerotic lesions than their female counterparts (17.1% versus 12.9%). Male recipient ApoE−/− mice had slightly enhanced atherosclerotic lesion formation than female recipient ApoE−/− mice (2.5-fold, P = 0.0001, versus 1.8-fold, P = 0.0001) when transplanted with AEBP1TG BM cells. Consistently, aortic root sections stained with ORO also revealed elevated accumulation of lipid deposits in the aortas of ApoE−/−/TG-BM mice in a gender-influenced manner (4.7-fold, P = 0.0001, versus 3.0-fold, P = 0.0001) (Figure 5C). Notably, although transplantation of AEBP1TG BM cells into ApoE−/− mice led to a significant elevation of plasma cholesterol and triglyceride levels in male and female recipients (Figure 5D), this difference did not reach statistical significance, as in the case of AEBP1TG males (Figure 1).
BM-Derived AEBP1 Promotes Atherosclerosis by Downregulating Cholesterol Efflux Mediators PPARγ1 and LXRα and Provoking Macrophage Inflammatory Responsiveness
We have previously shown that AEBP1 promotes foam cell formation by down-regulating PPARγ1, LXRα and their downstream target genes (9,11). To examine whether AEBP1 modulates PPARγ1 and LXRα expression in macrophages of the chimeric mice, macrophage protein extracts were subjected to immunoblotting (Figure 6A). Quantification analysis revealed more than a 3.0-fold (P = 0.0001) and 1.8-fold (P = 0.0001) decrease in protein levels of PPARγ1 and LXRα, respectively, in ApoE −/−/TG-BM macrophages (Figure 6b). Similarly, real-time PCR analysis revealed that transplantation of AEBP1TG BM cells into ApoE−/− mice leads to a 2.7-fold (P = 0.0001) reduction in PPARγ1 levels in ApoE−/−ITG-BM macrophages compared with ApoE−/−/NT-BM control macrophages (Figure 6C). Moreover, the expression of major cholesterol efflux mediators (ApoE, ABCA1 and ABCG1, which are downstream target genes of PPARγ1 and LXRα) was significantly reduced (2.8-, 1.4- and 1.5-fold, respectively) in ApoE−/−/TG-BM macrophages compared with ApoE−/−/NT-BM control macrophages (see Figure 6C).
Proinflammatory cytokines have been implicated as key mediators in atherogenesis. We have previously shown that AEBP1 overexpression in macrophages is accompanied by a significant increase in the production of major proinflammatory mediators including IL-6 and tumor necrosis factor (TNF)-α (9). Here, the expression of IL-6 and TNF-α was examined in the macrophages of BM-chimeric ApoE−/− mice. As shown in Figure 6C, IL-6 and TNF-α levels were significantly (P = 0.0001) elevated (1.8- and 1.6-fold, respectively) in ApoE−/−/TG-BM macrophages compared with ApoE−/−/NT-BM control macrophages. Taken together, these results strongly suggest that macrophage AEBP1 exerts a potent pro-atherogenic function in vivo.
It has been well established that mice are particularly resistant to the formation of atherosclerotic lesions (19,20). Even when fed a HCD (100 times their normal daily intake), mice do not show signs of atherogenesis (21). Nevertheless, two widely recognized genetically altered mouse models exist that spontaneously develop lesions; ApoE−/− mice fed a standard diet (22,23) and LDLR−/− mice fed a HCD (24). In this study, we identify AEBP1TG mice as a novel murine model of atherosclerosis. AEBP1TG mice develop relatively small, atypical atherosclerotic lesions that are surrounded by very thin, poorly characterized fibrous caps, and the lesions are not continuous along the endothelial monolayer. These results may be due to differential athero-susceptibility by different strains of mice (25–27). AEBP1TG mice were raised on the FVB/N background, whereas ApoE−/− and LDLR−/− mice were raised on the C57BL/6 background. It is documented that the mean lesion area is 3.5- to 9-fold higher in ApoE−/− mice raised on the C57BL/6 background, compared with ApoE−/− mice raised on the FVB/N background (26). The fact that FVB/N mice are relatively athero-resistant coupled with the high athero-susceptibility exhibited by AEBP1TG mice reflects the robust atherogenic potential of AEBP1. Here, a number of points are noteworthy. First, no atherosclerotic lesions are detected in chow diet-fed AEBP1TG mice, suggesting that AEBP1TG mice resemble LDLR−/− mice with regard to their ability to form lesions in a diet-induced manner. Interestingly, AEBP1 expression is induced in the macrophages of mice fed an HFD (A Majdalawieh and H-S Ro, unpublished observations). We have previously shown that AEBP1 expression is also induced in the adipose tissues of mice fed an HFD (13). These results suggest that a critical level of AEBP1 is necessary for the lesion formation in AEBP1TG mice. Second, although lesions are detected in both genders of AEBP1TG mice, females develop lesions more prevalently (see Table 1) and of a larger mean area (see Table 2). Despite the low number of samples used, these data are consistent with other studies suggesting that HFD-fed female mice are more susceptible to lesion formation compared with HFD-fed male mice (27–30). Several explanations were provided to account for gender-specific differences with regard to athero-susceptibility (27–32). The only satisfactory explanation for the gender-specific, athero-susceptibility differences in AEBP1TG mice is that AEBP1TG females, but not males, have significantly elevated cholesterol and triglyceride serum levels compared with their AEBP1NT counterparts (Figure 1A). This gender-specific effect is most unlikely due to alteration of sex hormones in the AEBP1TG females, in which assessment of serum estrogen levels did not reveal any significant difference between AEBP1TG females and AEBP1NT counterparts (unpublished observations).
Many studies have demonstrated that promotion or inhibition of atherogenesis is not always preceded or accompanied by changes in the plasma lipoprotein profile (31,33,34). Here, it is important to emphasize that atherogenesis can be initiated and advanced despite normal plasma lipoprotein profile. Interestingly, AEBP1TG males, which have plasma cholesterol and triglyceride levels that are statistically comparable to their AEBP1NT male counterparts (see Figure 1A), clearly develop atherosclerotic lesions (see Table 1). Hence, these findings lend support to the inflammatory aspect of atherosclerosis, which can develop despite normal plasma lipoprotein profile. Interestingly, AEBP1TG mice seem to be relatively resistant to elevated cholesterol levels upon HFD challenge. Whereas HFD-fed ApoE−/− and LDLR−/− mice display approximately six-fold elevation in plasma cholesterol levels (1,800 and 1,500 mg/dL, respectively), HFD-fed AEBP1TG females have less than two-fold elevated cholesterol levels than their HFD-fed AEBP1NT counterparts (see Figure 1A). So, AEBP1TG mice may serve as a preferred in vivo model to elucidate the inflammatory events during atherogenesis in the absence of severe hyperlipidemia.
Macrophages isolated from AEBP1TG males express significantly higher levels of IL-6, TNF-α, monocyte chemoattractant protein 1 (MCP-1) and inducible nitric oxide synthase (iNOS) than macrophages isolated from AEBP1NT mice (9), confirming that inflammation is a critical event in atherogenesis. In fact, there is a general consensus among researchers that hyper-lipidemia is not sufficient on its own to lead to the development of advanced atherosclerotic lesions and that inflammatory events such as monocyte recruitment, macrophage activation, cytokine and chemokine production and infiltration of other immune cells (for example, T cells, neutrophils and mast cells) are critical for atherosclerotic lesion initiation and progression. Interestingly, AEBP1 ablation reduces atherosclerotic lesion area and causes reduction of T-cell number in LDLR−/− mice (see Figure 2). It has been previously shown that infiltration of Tcells into the atherosclerotic lesions is a crucial event in the early phase of atherogenesis, and as the disease progresses, macrophage recruitment and activation intensify and macrophages become the predominant cell type during the late phase of atherosclerosis (35–38). It is interesting to speculate that AEBP1 is not only important in controlling macrophage infiltration during the late phase of atherogenesis, but it may also be critically involved in the early phase of the disease.
To enable investigation of a potential direct and specific role of AEBP1 in atherogenesis, we generated AEBP1TG/LDLR−/− hybrid mice. However, atherosclerotic lesion analysis in the hybrid mice did not yield any meaningful results, possibly because of the mixed-strain effect on atherosclerotic lesion development in the hybrid mice. To avoid the strain effect, we generated AEBP1−/−/ LDLR−/− double-knockout mice on the same C57BL/6 background. These double-knockout mice exhibited significant resistance to atherosclerotic lesion development compared with the control AEBP1+/+/LDLR−/− mice (see Figure 2). However, this may be due to a compound effect of global disruption of AEBP1 in the double-knockout mice (see Figure 3). To definitively evaluate the functional role of AEBP1 signaling in atherogenesis and to investigate a direct role of macrophage AEBP1 in the development of atherosclerosis, we also generated chimeric mice by BM transplantation. Experimental evidence suggests that while transplantation of AEBP1−/− BM cells into LDLR−/− recipients attenuates lesion formation (see Figure 4), transplantation of AEBP1TG BM cells into ApoE−/− recipients enhances lesion formation (see Figure 5) by downregulating cholesterol efflux mediators PPARγ1 and LXRα and provoking macrophage inflammatory responsiveness (see Figure 6). Our findings strongly suggest that macrophage AEBP1 plays a critical role in the development of atherosclerosis. The potential pro-atherogenic properties of AEBP1 may be a byproduct of a vital interplay of its ability to antagonize PPARγ1 and LXRα cholesterol efflux functions in macrophages and its ability to promote inflammation via enhanced NF-κB transcriptional activity (39,40). We anticipate that AEBP1 may serve as a molecular candidate toward the development of therapeutic strategies to ameliorate or attenuate atherogenesis.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
Ross R. (1999) Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:115–26.
Libby P. (2002) Inflammation in atherosclerosis. Nature. 420:868–74.
Ricote M, et al. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. U. S. A. 95:7614–9.
Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241–52.
Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93:229–40.
Venkateswaran A, et al. (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. U. S. A. 97:12097–102.
Chawla A, et al. (2001) A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:161–71.
Ro H-S, Kim SW, Wu D, Webber C, Nicholson TE. (2001) Gene structure and expression of the mouse adipocyte enhancer-binding protein. Gene. 280:123–33.
Majdalawieh A, Zhang L, Fuki IV, Rader DJ, Ro H-S. (2006) Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. Proc. Natl. Acad. Sci. U. S. A. 103:2346–51.
Majdalawieh A, Zhang L, Ro H-S. (2007) Adipocyte enhancer-binding protein-1 promotes macrophage inflammatory responsiveness by up-regulating NF-kappaB via IkappaBalpha negative regulation. Mol. Biol. Cell. 18:930–42.
Majdalawieh A, Ro H-S. (2009) LPS-induced suppression of macrophage cholesterol efflux is mediated by adipocyte enhancer-binding protein 1. Int. J. Biochem. Cell. Biol. 41:1518–25.
Ro H-S, et al. (2007) Adipocyte enhancer-binding protein 1 modulates adiposity and energy homeostasis. Obesity. 15:288–302.
Zhang L, et al. (2005) The role of AEBP1 in sexspecific diet-induced obesity. Mol. Med. 11:39–47.
Palinski W, et al. (1994) ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14:605–16.
Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. (1998) A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J. Clin. Invest. 101:353–63.
Cybulsky MI, et al. (2001) A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107:1255–62.
Zhou X, Stemme S, Hansson GK. (1996) Evidence for a local immune response in atherosclerosis: CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 149:359–66.
Bays HE. (2009) “Sick Fat,” metabolic disease, and atherosclerosis. Am. J. Med. 122:S26–37.
Zhang SH, Reddick RL, Piedrahita JA, Maeda N. (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468–71.
Breslow JL. (1996) Mouse models of atherosclerosis. Science. 272:685–8.
Reardon CA, Getz GS. (2001) Mouse models of atherosclerosis. Curr. Opin. Lipidol. 12:167–73.
Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 89:4471–5.
Plump AS, et al. (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343–53.
Ishibashi S, et al. (1993) Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:883–93.
Paigen B, Mitchell D, Holmes PA, Albee D. (1987) Genetic analysis of strains C57BL/6J and BALB/cJ for Ath-1, a gene determining atherosclerosis susceptibility in mice. Biochem. Genet. 25:881–92.
Dansky HM, et al. (1999) Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 19:1960–8.
Smith JD, et al. (2003) In silico quantitative trait locus map for atherosclerosis susceptibility in apolipoprotein E-deficient mice. Arterioscier. Thromb. Vasc. Biol. 23:117–22.
Paigen B, Holmes PA, Mitchell D, Albee D. (1987) Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis. 64:215–21.
Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. (1987) Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68:231–40.
Ishii I, Ito Y, Morisaki N, Saito Y, Hirose S. (1995) Genetic differences of lipid metabolism in macrophages from C57BL/6J and C3H/HeN mice. Arterioscler. Thromb. Vasc. Biol. 15:1189–94.
Song C, Hiipakka RA, Liao S. (2001) Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids. 66:473–9.
Smith JD, Dansky HM, Breslow JL. (2001) Genetic modifiers of atherosclerosis in mice. Ann. N.Y. Acad. Sci. 947:247–53.
Gu L, et al. (1998) Absence of monocyte chemo-attractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell. 2:275–81.
Tsukamoto K, et al. (2000) Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol. Ther. 1:189–94.
Song L, Leung C, Schindler C. (2001) Lymphocytes are important in early atherosclerosis. J. Clin. Invest. 108:251–9.
Roselaar SE, Kakkanathu PX, Daugherty A. (1996) Lymphocyte populations in atherosclerotic lesions of apoE−/— and LDL receptor−/— mice: decreasing density with disease progression. Arterioscler. Thromb. Vasc. Biol. 16:1013–8.
Zhou X, Nicoletti A, Elhage R, Hansson GK. (2000) Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 102:2919–22.
Hansson GK, Hermansson A. (2011) The immune system in atherosclerosis. Nat. Immunol. 12:204–12.
Majdalawieh A, Ro HS. (2010) PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl. Recept. Signal. 8:e004.
Majdalawieh A, Ro HS. (2010) Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm. 2010:823821.
We thank Chris Webber, Janette Flemming, Debby Currie and Patricia Colp for their technical assistance. This work was supported by a grant from the Canadian Institutes of Health Research (to H-S Ro).
Electronic supplementary material
Adipocyte Enhancer-Binding Protein 1 (AEBP1) (a Novel Macrophage Proinflammatory Mediator) Overexpression Promotes and Ablation Attenuates Atherosclerosis in ApoE−/− and LDLR−/− Mice
About this article
Cite this article
Bogachev, O., Majdalawieh, A., Pan, X. et al. Adipocyte Enhancer-Binding Protein 1 (AEBP1) (a Novel Macrophage Proinflammatory Mediator) Overexpression Promotes and Ablation Attenuates Atherosclerosis in ApoE−/− and LDLR−/− Mice. Mol Med 17, 1056–1064 (2011). https://doi.org/10.2119/molmed.2011.00141
- Adipocyte Enhancer-binding Protein (AEBP1)
- Low-density Lipoprotein Receptor (LDLR)
- ATP-binding Cassette A1 (ABCA1)
- ATP-binding Cassette G1 (ABCG1)
- Macrophage Inflammatory Responsiveness